| Symbol | PLRX |
|---|---|
| Name | PLIANT THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 331 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, California, 94080, United States |
| Telephone | +1 650 481-6770 |
| Fax | — |
| — | |
| Website | https://www.pliantrx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001746473 |
| Description | Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Its lead product candidate, PLN-74809, is an oral small-molecule dual that helps in the treatment of idiopathic pulmonary fibrosis. Additional info from NASDAQ: |
Director CROWELL GAYLE A 🟢 acquired 70.0K shares (1 derivative) of PLIANT THERAPEUTICS, INC. (PLRX) at $1.14 Transaction Date: Jun 11, 2026 | Filing ID: 000104
Read moreDirector MCCOURT Thomas A 🟢 acquired 70.0K shares (1 derivative) of PLIANT THERAPEUTICS, INC. (PLRX) at $1.14 Transaction Date: Jun 11, 2026 | Filing ID: 000103
Read moreDirector Krognes Steve E. 🟢 acquired 70.0K shares (1 derivative) of PLIANT THERAPEUTICS, INC. (PLRX) at $1.14 Transaction Date: Jun 11, 2026 | Filing ID: 000102
Read moreDirector Curnutte John T 🟢 acquired 70.0K shares (1 derivative) of PLIANT THERAPEUTICS, INC. (PLRX) at $1.14 Transaction Date: Jun 11, 2026 | Filing ID: 000101
Read moreDirector Huh Hoyoung 🟢 acquired 70.0K shares (1 derivative) of PLIANT THERAPEUTICS, INC. (PLRX) at $1.14 Transaction Date: Jun 11, 2026 | Filing ID: 000100
Read moreDirector Cline Darren S 🟢 acquired 70.0K shares (1 derivative) of PLIANT THERAPEUTICS, INC. (PLRX) at $1.14 Transaction Date: Jun 11, 2026 | Filing ID: 000099
Read more(99% Neutral) PLIANT THERAPEUTICS, INC. (PLRX) Announces Regulatory Update
Read morePliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Read more(10% Negative) PLIANT THERAPEUTICS, INC. (PLRX) Reports Q2 2026 Financial Results
Read morePliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06097260 | Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809… | Phase2 | Idiopathic Pulmonary Fibrosis | Terminated | 2023-11-16 | 2025-04-04 | ClinicalTrials.gov |
| NCT06270706 | A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors | Phase1 | Advanced or Metastatic Solid Tumor | Recruiting | 2023-08-30 | 2030-06-01 | ClinicalTrials.gov |
| NCT05621252 | Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809) | Phase2 | Idiopathic Pulmonary Fibrosis | Completed | 2022-07-13 | 2024-01-08 | ClinicalTrials.gov |
| NCT04565249 | Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Pa… | Phase2 | Acute Respiratory Distress Syndrome | Terminated | 2020-10-22 | 2021-08-02 | ClinicalTrials.gov |
| NCT04480840 | Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 … | Phase2 | Primary Sclerosing Cholangitis | Completed | 2020-07-27 | 2024-03-18 | ClinicalTrials.gov |
| NCT04396756 | Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulm… | Phase2 | Idiopathic Pulmonary Fibrosis | Completed | 2020-03-03 | 2023-02-15 | ClinicalTrials.gov |
| NCT04072315 | Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging i… | Phase2 | Idiopathic Pulmonary Fibrosis | Completed | 2020-02-13 | 2022-07-05 | ClinicalTrials.gov |
| NCT03183570 | Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT | Early_Phase1 | Idiopathic Pulmonary Fibrosis | Completed | 2017-11-08 | 2025-01-25 | ClinicalTrials.gov |
| NCT02321254 | Myoelectric Robot-assisted Rehabilitation for the Upper Limb After Stroke | Phase1 | Stroke | Completed | 2014-05-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT00405691 | Safety and Effectiveness Study of the TOPS System, a Total Posterior Arthroplas… | Phase3 | Low Back Pain | Completed | 2006-09-01 | — | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| "TOPS System" - Total Posterior Arthroplasty Implant | Other | Phase PHASE3 | Low Back Pain | COMPLETED | NCT00405691 |
| "TOPS System" - Total Posterior Arthroplasty Implant | Other | Phase PHASE3 | Low Back Pain | COMPLETED | NCT00405691 |
| Standard rehabilitation therapy | Drug | Phase PHASE1 | Stroke | COMPLETED | NCT02321254 |
| The RehaARM-Robot | Other | Phase PHASE1 | Stroke | COMPLETED | NCT02321254 |
| Standard rehabilitation therapy | Drug | Phase PHASE1 | Stroke | COMPLETED | NCT02321254 |
| The RehaARM-Robot | Other | Phase PHASE1 | Stroke | COMPLETED | NCT02321254 |
| Placebo | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome | TERMINATED | NCT04565249 |
| PLN-74809 | Other | Phase PHASE2 | Acute Respiratory Distress Syndrome | TERMINATED | NCT04565249 |
| Knottin tracer | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT04072315 |
| PLN-74809 | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT04072315 |
| Placebo | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT04396756 |
| PLN-74809 | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT04396756 |
| [18F]FP-R01-MG-F2 | Other | Phase EARLY_PHASE1 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT03183570 |
| Placebo | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT06097260 |
| PLN-74809 | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT06097260 |
| Placebo | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT05621252 |
| PLN-74809 | Other | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT05621252 |
| Placebo | Other | Phase PHASE2 | Primary Sclerosing Cholangitis | COMPLETED | NCT04480840 |
| PLN-74809 | Other | Phase PHASE2 | Primary Sclerosing Cholangitis | COMPLETED | NCT04480840 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumor | RECRUITING | NCT06270706 |
| PLN-101095 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumor | RECRUITING | NCT06270706 |
| Pembrolizumab | DRUG | Phase PHASE1 | Metastatic Solid Tumor | RECRUITING | NCT06270706 |
| PLN-101095 | DRUG | Phase PHASE1 | Metastatic Solid Tumor | RECRUITING | NCT06270706 |
| Placebo | DRUG | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT06097260 |
| Knottin tracer | RADIATION | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT04072315 |
| PLN-74809 | DRUG | Phase PHASE2 | Idiopathic Pulmonary Fibrosis | TERMINATED | NCT06097260 |
| [18F]FP-R01-MG-F2 | DRUG | Phase EARLY_PHASE1 | Idiopathic Pulmonary Fibrosis | COMPLETED | NCT03183570 |